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Abstract
Background  and  objective:  Anaphylaxis  remains  one  of  the  potential  causes  of  perioperative
death, being  generally  unanticipated  and  quickly  progress  to  a  life  threatening  situation.  A
narrative  review  of  perioperative  anaphylaxis  is  performed.
Content:  The  diagnostic  tests  are  primarily  to  avoid  further  major  events.  The  mainstays  of
treatment  are  adrenaline  and  intravenous  ﬂuids.
Conclusion:  The  anesthesiologist  should  be  familiar  with  the  proper  diagnosis,  management
and monitoring  of  perioperative  anaphylaxis.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Resumo
Antecedentes  e  objetivo:  A  anaﬁlaxia  continua  sendo  uma  das  causas  potenciais  de  morte  peri-
operatória  pois  geralmente  não  é  prevista  e  evolui  rapidamente  para  uma  situac¸ão  ameac¸adora
da vida.  Uma  revisão  da  anaﬁlaxia  perioperatória  é  realizada.
Conteúdo:  O  exames  diagnósticos  são  importantes  principalmente  para  evitar  eventos  posteri-
ores. Os  pilares  do  tratamento  são  a  adrenalina  e  os  líquidos  intravenosos.
Conclusão:  O  anestesiologista  deve  estar  familiarizado  com  o  diagnóstico  oportuno,  manejo  e
monitoramento  da  anaﬁlaxia  perioperatória.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.E-mail: martaberrio@gmail.com (M.I. Berrío Valencia).
ttp://dx.doi.org/10.1016/j.bjane.2014.09.002
104-0014/© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
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Introduction
The  immediate  hypersensitivity  reactions  occur  in  1  out  of
5000--10,000  anesthesias.1 The  variability  occurs  because  it
is  based  on  retrospective  studies  with  a  calculated  incidence
according  to  voluntary  information  and  the  number  of  previ-
ous  anesthesias  performed,  which  may  lead  to  undercounts.2
Sixty  percent  of  perioperative  hypersensitivity  reactions  are
allergic,  with  a  mortality  rate  of  3--9%.3 In  this  review
the  etiology,  symptomatology,  diagnosis  and  treatment  of
perioperative  anaphylaxis  are  assessed  with  some  ﬁnal  rec-
ommendations.  This  review  does  not  focus  on  latex  allergy.
Methodology
A  literature  search  was  performed  in  PubMed,  LILACS  and
Google  Scholar,  with  no  restriction  of  dates  or  types  of
articles;  in  PubMed  the  following  MeSH  terms  were  used:
anaphylaxis,  hypersensitivity,  anesthesia,  perioperative  and
treatment.  The  snowball  method  was  used.
Deﬁnition
The  European  Academy  of  Allergy  and  Clinical  Immunology
deﬁnes  anaphylaxis  as  a  reaction  of  severe  life-threatening
generalized  or  systemic  hypersensitivity.4,5 Perioperative
anaphylaxis  is  a  systemic  reaction  that  occurs  during  anes-
thesia  induction  minutes  after  intravenous  (IV)  induction.6,7
However,  the  agents  administered  through  other  routes,
such  as  chlorhexidine,  latex  or  methylene  blue  may  also
cause  the  reaction  after  15  min6 during  maintenance  of  anes-
thesia  or  during  recovery  due  to  absorption  by  the  skin,
mucosa  or  tourniquet  removal.8
Types
The  World  Allergy  Organization  (WAO)  has  pro-
posed  the  classiﬁcation  of  anaphylaxis  in  immune
and  non-immune.4 The  immune  anaphylaxis  includes
immunoglobulin  (Ig)  E-mediated,  IgG-mediated  and  immune
complex/complement-mediated  reactions.4
Immunoglobulin E-mediated anaphylaxis
PhysiopathologyThis  type  of  anaphylaxis  is  an  immediate  IgE-mediated
hypersensitivity  systemic  reaction  with  release  of  pro-
inﬂammatory  mediators  from  mast  cells  and  basophiles.9
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Table  1  Factors  that  enhance  anaphylaxis  risk.
Age  range  Gender  Pathologies  
Nursing  mothers  Female  Asthma  
Elderly Systemic  mastocytos
ACEI, angiotensin-converting enzyme inhibitor.293
he  mediators  are  histamine,  triptase,  cytokines,  medi-
tors  derived  from  phospholipids  as  prostaglandin  D2,
eukotrienes,  thromboxane  A2 and  platelet  activating  fac-
or  involved  in  the  clinical  presentation.1,10 Target  organs
re  the  skin,  mucous  membranes  and  the  respiratory,  car-
iovascular  and  gastrointestinal  systems.1,10 In  IgE-mediated
rug  anaphylaxis  prior  contact  with  the  agent  is  not  required
nd  sensibility  can  occur  through  cross-reactivity.1
The  non-immune  anaphylaxis  is  clinically  indistinguish-
ble  from  IgE-mediated  anaphylaxis.11
tiology
he  risk  of  anaphylaxis  increases  with  frequency,  the  par-
nteral  route  of  administration  and  the  speciﬁc  antigen
xposure  time.9 Table  1  presents  risk  factors  for  the  devel-
pment  of  anaphylaxis.3 Also,  there  are  comorbidities  and
rugs  that  enhance  the  severity  of  the  symptoms  and
ecrease  the  response  to  treatment,  such  as  heart  dis-
ases,  chronic  lung  disease,  recent  intracranial  surgery,  and
yperthyroidism.4
The  main  etiological  agents  of  perioperative  anaphy-
axis  are  the  neuromuscular  blocking  agents,  followed  by
atex  and  then  the  antibiotics.12--16 Anaphylaxis  to  halo-
enated  agents  has  never  been  reported.14 Allergic  reactions
o  local  anesthetics  are  very  rare.17 Other  substances
hat  can  cause  immediate  allergies  at  perioperative  period
re  aprotinin,  chlorhexidine,  heparin,  methylene  blue  and
nti-inﬂammatory  steroids.17 Anaphylaxis  to  neuromuscular
lockers  can  occur  during  the  ﬁrst  exposure,17,18 has  a  high
ncidence  of  cross-reactivity  among  the  various  neuromus-
ular  blockers,  and  is  more  frequent  in  women  (2:1--8:1);18
he  most  involved  is  the  suxamethonium.17
linical features
he  clinical  presentation  of  anaphylaxis  is  characterized  by
ts  variability  among  patients  and  even  in  the  same  patient
rom  one  episode  to  another.19 Clinical  anaphylaxis  during
nesthesia  can  be  masked  or  confused  with  hypovolemia,
epth  of  anesthesia  and  extended  regional  block.6,10,20 The
ncreased  vascular  permeability  by  35%  within  10  min  and
he  intrinsic  compensatory  response  to  endogenous  cate-
holamines  inﬂuence  clinical  manifestations.21 The  most
ommon  initial  signs  are  no  pulse,  difﬁcult  ventilation  and
esaturation.14,22 Another  sign  is  the  reduction  of  expired
arbon  dioxide14,23 values.
There  is  a  classiﬁcation  of  the  severity  of  symptoms
n  grades  1--5.24 The  perioperative  cardiovascular  collapse
s  the  most  common  trait  (88%  of  cases)  and  the  worst
Ampliﬁers  Severity
Fever  Beta-blocker  use
is  Active  infection  ACEI  use
Pre-menstrual  state  Spinal  anesthesia
Emotional  state
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Table  2  First-line  treatment.
Withhold  all  potential  causes
Stop  halogenated  agents
100%  oxygen
Inform  the  surgeon.  Postpone  surgery
Ask  for  help
Intubate
Trendelenburg,  if  not  contraindicated
IV Adrenalin  or  IM  if  IV  not  available
Crystalloids
Second  IV  access
Transfer  to  ICU/SCU
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ign.7,22 Anaphylaxis  can  be  fatal  within  the  ﬁrst  5--30  min
f  its  presentation25,26 with  an  incidence  of  cardiac  arrest  of
0%.7,22 Myocardial  ischemia,  acute  myocardial  infarction,
rrhythmias  and  myocardial  depression  may  contribute  to
emodynamic  deterioration  and  cardiac  arrest,27 occurring
ven  before  administration  of  adrenalin.28--31
Skin  symptoms,  such  as  stiffness,  hives  and  swelling,  are
ecognized  in  70%  of  cases7,22 and  during  anesthesia  may  be
idden  in  the  surgical  ﬁelds.10
Ten  to  fourteen  percentage  of  the  reactions,  especially
he  severe  ones,  affect  only  one  system,  fundamentally  car-
iovascular  collapse  and  bronchospasm,  which  lead,  in  many
ases,  to  other  diagnoses.14,32 Moreover,  heart  failure  is  the
nly  sign  present  in  the  reaction,  in  51.7%  of  cases;33 there-
ore,  when  any  of  the  previous  signs  take  place,  the  protocol
or  allergic  reactions  should  be  conducted.2
Other  signs  and  symptoms  are  swelling  of  the  tongue,
ips  and  uvula,  stridor,  hypoxemia,  incontinence,  abdominal
ain,  nausea,  vomiting,  rhinorrhea,  among  others.4 It  is  nec-
ssary  to  consider  that  general  anesthesia  can  mask  many
anifestations.  In  children,  the  skin  signs  and  symptoms
ccur  in  most  cases,  bronchospasm  is  the  most  concerning
anifestation,  and  hypotension  and  shock  are  not  common
t  the  onset  of  the  problem.8
iagnostic tests
he  diagnosis  of  anaphylaxis  is  mainly  clinical.4 The  lack  of
xperience,  the  lack  of  view  of  the  patient’s  body,  and  the
aried  use  of  medication  during  anesthesia  make  it  difﬁcult
o  establish  a  proper  diagnosis.6 There  are  some  tests  such
s  measurement  of  triptase,  histamine  and  IgE  levels,  but
one  has  absolute  accuracy.8
Skin  tests  can  identify  the  causative  agent  but  they  are
erformed  after  the  month  in  which  anaphylaxis  occurred,
hich  restricts  its  use  to  prevent  further  cases.10,34
ryptase
ryptase  is  a  serine  protease  that  has  several  main  forms.35
he  serum  tryptase  concentration  due  to  mast  cell  degra-
ulation  is  300--700  times  higher  than  that  released  by
asophiles.2 An  increase  exceeding  25  g  L−1 is  consid-
red  an  indicator  of  anaphylaxis.2 Tryptase  levels  can  be
ncreased  by  other  diseases  such  as  systemic  mastocytosis,
ast  cell  activation  syndrome  or  hematological  diseases.17
n  the  other  hand,  a  normal  level  of  tryptase  does  not  rule
ut  a  diagnosis  of  anaphylaxis.2,4
The  half-life  of  tryptase  is  120  min8 and  the  levels  return
o  baseline  in  24  h.35 There  may  be  false  positives  due  to
evere  stress  such  as  major  trauma  or  hypoxemia.8 The  sam-
le  should  be  collected  from  15  min  to  3  h  from  the  onset  of
ymptoms,4 and  after  24  h.36 A  coagulated  blood  sample  of
--10  mL36 is  collected,  along  with  clinical  history  data37 and
ample  collection  time  at  the  onset  of  reaction.10reatment
he  early  treatment  is  essential  in  anaphylaxis  and  could
void  hypoxic-ischemic  encephalopathy  or  death.38 The
o
c
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5Inform  family
ICU, intensive care unit; SCU, semi intensive care unit.
anagement  is  basically  the  same  in  all  ages,  considering
he  adjustment  by  weight  in  children.4 The  mainstays  of
reatment  are  adrenaline  and  IV  liquids.10
Interventions  in  anaphylaxis  are  based  on  recommen-
ations  of  experts  as  the  realization  of  prospective,  ran-
omized,  double-blind,  placebo-controlled  studies  cannot
e  performed  when  there  is  an  unpredictable  condition.19,39
uring  anesthesia,  the  patient  is  monitored  and  has  venous
ccess.10 The  team  should  be  prepared  to  perform  various
asks  simultaneously;36 investigate  potential  causes  such  as
atex,  chlorhexidine,  blood  products,  and  maintain  anesthe-
ia,  if  necessary,  with  only  halogenated  agents,36 request
elp,  take  note  of  the  time  and  inform  the  surgeon.34,36
he  advanced  and  fast  airway  management  is  critical  to
he  development  of  laryngeal  or  oropharyngeal  edema.27
 hundred  percent  oxygen  should  be  administered;  if  not
ontraindicated,  lower  limbs  should  be  elevated,7,40 and  in
dults  500--1000  mL  of  crystalloids7 in  10--20  min  should  be
iven;  in  children  bolus  of  20  mL  kg−1,  if  they  need  more
han  40  mL  kg−1 add  support  vasopressor,41 titrate  to  main-
ain  a systolic  blood  pressure  above  90  mmHg  in  adults,27
deally  with  invasive  monitoring  of  blood  pressure.41 WAO
ecommends  the  use  of  normal  saline,  rather  than  colloids.38
Adrenaline  is  the  treatment  of  choice  in  anaphylaxis5
or  its  alpha  and  beta-agonist  properties,  resulting  in
asoconstriction,  increased  peripheral  vascular  resistance,
ecreased  mucosal  edema,  inotropism,  and  chronotropism
nd  bronchodilation.28,42,43 The  IV  dose  of  adrenalin  at
0--200  g  varies  depending  on  the  patient’s  hemodynamic
nvolvement  and  can  be  repeated  every  1--2  min.17 In  chil-
ren  the  dose  is  1  g  kg.17,36
The  intramuscular  route  can  be  used  if  there  is  no  IV
ccess.36 The  best  application  is  in  the  anterolateral  aspect
f  the  middle  muscle  as  it  provides  greater  absorption,  each
 min,  both  in  children  and  in  adults;44 doses  of  0.5  mg  in
dults.17
In  patients  who  require  repeated  bolus,  continuous
nfusion  of  0.05--0.1  g  kg−1 min−1 should  be  started,  an
itrated.10,45,46 Table  2  shows  a  checklist  of  the  acute  man-
gement  of  anaphylaxis.
Patients  using  beta  blockers  may  require  high  doses
f  adrenaline  when  they  have  a  poor  response;  in  these
ases  norepinephrine  should  be  added  at  a  dose  of
.1  g  kg−1 min−1.17 IV  glucagon10 1--2  mg  IV  can  be  used  each
 min,34 followed  by  5--15  g  min−1,17 vasopressin  2--0  UI  IV
Perioperative  anaphylaxis  
Table  3  No  response  to  adrenalin.
Norepinephrine
Vasopressin  2--10  U  IV
Glucagon  IV  1--2  mg  IV  each  5  min
Reports:  methylene  blue
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TReports:  sugammadex  16  mg  kg IV  in  anaphylaxis  to
rocuronium
according  to  response  dose6 as  shown  in  Table  3.  In  chil-
dren  vasopressin17 is  not  recommended.  There  are  reports
of  cases  of  use  of  methylene  blue  in  severe  unresponsive
anaphylactic  shock.18,47 In  the  case  of  anaphylaxis  to  rocuro-
nium,  the  successful  use  of  sugammadex  16  mg  kg−1 IV  is
described,  at  a  dose  according  to  the  situation  of  cannot
intubate,  cannot  ventilate.18
The  beta2-adrenergic  agents  relieve  bronchospasm,  but
not  upper  airway  obstruction  and  shock.48 The  patient
should  remain  under  observation  during  24  h  as  the  biphasic
reactions4 cannot  be  predicted.  In  case  of  cardiac  arrest,
the  basic  management  and  advanced  pattern  is  followed,
considering  that  it  is  preferable  to  continue  the  infusion  of
adrenaline  during  and  after  cardiac  arrest.27
In  the  second  line  of  anaphylaxis  treatment  line  are
glucocorticoids,  the  doses  of  which  extrapolate  asthma  man-
agement  and  its  onset  of  action  takes  several  hours,38 and
there  is  no  evidence  of  its  use  in  the  acute  management.5,49
A  dose  of  200  mg  IV  of  hydrocortisone  is  recommended  in
over  12  years  of  age  and  100  mg  IV  to  those  of  6--12  years  of
age.36
Antihistamines  are  also  not  recommended  for  the  initial
management;  they  are  indicated  to  treat  hives,  pruritus5
and  rhinorrheia,26 considering  that  some  can  cause  hypoten-
sion  and  drowsiness.26 Diphenhydramine  1--2  mg  kg−1 IV  can
be  used,  maximum  50  mg  and  can  be  associated  with  raniti-
dine  50  mg  for  adults  or  1  mg  kg−1.50
Referral to allergologist
The  anesthesiologist  responsible  for  the  patient  should  make
a  referral  to  the  allergologist  if  during  general  anesthe-
sia  there  is  an  unexplained  reaction  of  severe  hypotension,
bronchospasm  or  edema  at  recuperation.14 This  referral  is
performed  in  order  to  conﬁrm  the  nature  of  the  reaction,
the  offender  drug,  the  possibility  of  cross-reactivity  and
recommendations  for  further  studies.1 The  referral  report
should  include  a  medical  history  of  allergic  reaction,  the
patient  demographics,  allergic  and  atopic  history,  the  medi-
cal  history  and  the  medications  they  take,  the  administered
drugs  and  the  chronological  sequence  of  administration,  the
detailed  description  of  the  reaction,  the  suspect  drug,  route
of  administration,  the  clinical  features,  the  degree  of  sever-
ity,  the  treatment  given,  the  evolution  and  the  duration  of
reaction.2 In  addition,  include  information  about  exposure
to  latex,  infusions  and  exposure  time,  interventions  such  as
central  line  or  urinary  catheter  and  food  allergies.51 Also,  all
substance  exposures  should  be  noted  in  the  anesthesia  and
referral  record,  including  those  used  by  the  surgeon,  even
if  they  are  not  IV,  such  as  local  anesthetics,  ﬂuid  irrigation,
latex,  disinfectants,  methylene  blue,  among  others.10
R295
o consider
here  should  be  access  to  protocols  for  the  management  of
naphylaxis.37,38
There  should  be  a  habit  of  reporting  the  adverse  reaction
o  drugs52 and  discussing  the  case  for  educational  purposes.
dditionally,  the  importance  of  referral  to  an  allergologist
hould  be  emphasized  to  the  patient.38 In  case  of  knowing
he  offender  drug,  it  should  be  put  on  the  electronic  medi-
al  record,  and  a  medical  identiﬁcation,  such  as  a  bracelet
hould  be  put  on.38
In  case  of  reaction  to  codeine  or  morphine,  none  of  the
wo  is  to  be  administered,  but  there  is  no  contraindication
o  other  opioids.17
If  allergic  to  seafood,  iodinated  media  is  not
ontraindicated.17 There  is  one  case  of  anaphylaxis  to
rotamine  in  a  patient  with  allergy  to  ﬁsh,  but  the
iterature  does  not  warrant  its  prohibition.17
If  there  is  any  allergy  to  egg  or  soybean,  propofol  may
e  administered.  There  is  a  single  case  of  hypersensitivity
o  propofol  in  a  patient  allergic  to  egg.17
ecommendations
hen  the  patient  is  submitted  to  anaphylaxis  study  with  a
ositive  test  and  requires  anesthesia,  one  should  avoid  the
dentiﬁed  agent  and  histamine-liberating  substances,  inject
he  drugs  slowly,  fractioned  and  separated,  if  possible,  and
e  prepared  to  treat  an  anaphylactic  reaction.45
When  a  patient  who  has  a  history  of  cardiovascular  col-
apse  in  a previous  anesthesia  presents  for  urgent  surgery,
ith  no  study  of  anaphylaxis,  care  should  be  provided  in
 latex-free  environment,  with  the  use  of  halogenated
gents;  in  case  of  having  previous  record  of  anesthesia,
void  all  medications  used  prior  to  collapse,  except  for
alogenated  agents,  and  avoid  all  neuromuscular  block-
ng  agents  in  the  event  of  one  being  previously  used.18 If
here  is  no  record  of  anesthesia,  all  neuromuscular  block-
rs  should  be  avoided  according  to  the  risk-beneﬁt  balance,
nd  regional  or  local  anesthesia  should  be  favored,  avoiding
hlorhexidine  (allergy  to  iodine  is  less  common)  and  avoid
istamine-releasing  drugs.18 There  is  no  evidence  that  pro-
hylaxis,  either  with  antihistamines  or  steroids,  prevent  or
educe  the  severity  of  reaction.18,53
Due  to  the  potentially  fatal  feature  of  anaphylaxis,  clin-
cal  suspicion  and  the  knowledge  of  the  management  are
undamental  to  the  impact  of  morbidity  and  mortality.  It
ould  also  be  perfect  that  a national  network  for  repor-
ing  of  cases  and  notiﬁcation  of  allergies  be  provided  among
ifferent  health  institutions.
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